INTRODUCTION
============

Liver cirrhosis is a global health and economic burden, causing significant mortality.[@B1] One of the severe complications in patients with cirrhosis is bacterial infection.[@B2] Bacterial infection is a major cause of acute decompensation in patients with cirrhosis and has been shown to be a trigger for developing acuteon-chronic liver failure in acute decompensated cirrhosis patients, which is a key prognostic determinant and is significantly associated with mortality.[@B3][@B4]

Spontaneous ascitic infection (SAI) is defined as an ascitic fluid infection without an obvious intra-abdominal contiguous source of infection and is one of the most common infections in patients with cirrhosis.[@B5] Patients with SAI can be classified into two groups: 1) Culture-negative neutrocytic ascites is diagnosed based on an ascitic fluid polymorphonuclear leukocyte (PMN) count ≥250/mm^3^ with a negative culture.[@B6] For these patients, antibiotic treatment is based on the physician\'s experience. 2) Culture-positive SAI includes spontaneous bacterial peritonitis (SBP) and bacterascites. The prognosis and severity of liver insufficiency in patients with SBP and bacterascites are highly comparable, and the 30-day mortality rates of these two types of patients are reported as 31.5% and 32%, respectively.[@B7][@B8]

Early SAI diagnosis contributes to effective antibiotic therapy and improved survival.[@B9] However, successful empirical antibiotic therapy must be based on local epidemiologic data. Previous studies have reported that gram-negative bacteria (GNB), mainly *Enterobacteriaceae*, are the major causative organisms of ascites.[@B10] While third-generation cephalosporins have been used as the first-line treatment for SBP for several years,[@B11] recently, an increase in multidrug-resistant (MDR) agents, such as extended spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae*, have been observed in healthcare-associated and nosocomial infections, leading to failure of antibiotic strategies based on third-generation cephalosporins or quinolones and poor outcomes.[@B12] Therefore, the European Association for the Study of the Liver (EASL) lately updated their recommendations of empirical antibiotic therapy for patients with SBP.[@B13] However, because of various antibiotic prescription patterns in different regions and microbiological changes over time, the prevalence of antibiotic-resistant pathogens and the pathogen spectrum substantially differ geographically,[@B3][@B14] and more evidence is required to support the application of empirical antibiotic management based on the EASL guidelines for cirrhotic patients with SBP to other regions. Thus, further studies with a larger sample size on bacteriological and drug resistance of culture-positive SAI are extremely urgent.

Cirrhotic patients with SBP are nearly 1.5-fold more likely to die within 28 days than those with non-SBP infection.[@B15] Two epidemiological studies of SBP have shown that delay in diagnostic paracentesis and inadequate treatment were independent predictors of mortality associated with SBP.[@B16][@B17] However, few studies have evaluated the specific risk factors for SAI mortality in patients with culture-positive acute decompensated cirrhosis.

Therefore, this study aimed to assess possible changes in the pathogen spectrum and in drug resistance in patients with acute decompensated cirrhosis with culture-positive SAI based on site of infection acquisition and to identify independent risk factors of 28-day mortality after the first culture-positive SAI episode.

MATERIALS AND METHODS
=====================

Study design
------------

We retrospectively studied patients admitted to 11 different teaching hospitals diagnosed with acute decompensated cirrhosis with culture-positive SAI from January 1, 2012 to May 30, 2018. The clinical history, physical examination, and laboratory and microbiological results were recorded in a pre-established electronic chart. For patients who presented with multiple culture-positive SAI during the study period, only the first episode was considered for analysis. The study was approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology, and the ethical committees of each center (IORG No: IORG0003571).

Definitions
-----------

Diagnosis of liver cirrhosis was established by ultrasonographic findings, CT, MRI, and biopsy.[@B12] Acute decompensation was defined as acute development of one or more major complications of liver disease, including acute development of large ascites (within less than 2 weeks; ultrasound ascites volume ≥150 mL), acute hepatic encephalopathy, acute gastrointestinal hemorrhage, and bacterial infection.[@B4] Definition of organ failure was based on the chronic liver failure consortium organ failure score.[@B4] SAI was classified as nosocomial if the infection was diagnosed beyond 48 h of admission; as healthcare-associated if diagnosis was made within 48 h of admission in patients requiring hospitalization for at least 2 days or paying more than two visits to the emergency department in the previous 90 days prior to infection or receiving chemotherapy/hemodialysis in the previous 30 days preceding the infection; and as community-acquired in all other cases.[@B18] SBP was defined as an ascitic fluid PMN count ≥250/mm^3^ with a positive culture result. Bacterascites was defined as a positive bacterial culture with ascitic fluid PMN count \<250/mm^3^. Definitions of blood stream infections, urinary tract infections, and skin and soft tissue infections were based on other studies.[@B19] Resistant microorganisms were defined as MDR if they demonstrated non-susceptibility to at least one agent in three and as extensively drug resistant (XDR) in case of non-susceptibility to at least one agent in all but two or fewer antimicrobial categories.[@B20]

Microbiology
------------

Identification and susceptibility tests of the isolated pathogens were carried out using the Vitek 2 automated system (BioMerieux, Craponne, France). All antibiotic susceptibilities were tested according to the Clinical and Laboratory Standard Institute guidelines.[@B21] Results of the antimicrobial susceptibility tests were available within 48--72 h after the ascitic fluid culture showed positive results.

Statistical analysis
--------------------

Categorical variables are presented as frequencies or percentages and were tested for significance with χ^2^ or Fisher\'s exact test. Parametric quantitative variables are presented as means±standard deviation and were tested for significance with Student\'s t-test. Non-parametric quantitative variables are presented as median and interquartile ranges and were tested for significance with the Mann-Whitney U or Kruskal-Wallis test. To identify independent risk factors for 28-day mortality, a Cox proportional hazards regression model was applied. Variables showing a statistically significant association with the outcome in univariate analysis (*p*\<0.1) were entered into multivariate analysis using stepwise backward selection (entry *p*\<0.05; drop *p*\>0.1) based on likelihood ratios for entering and dropping variables. In all statistical analyses, *p* values \<0.05 were considered statistically significant. Analyses were performed using SPSS statistical software, version 23.0 for Macintosh (IBM Corp., Armonk, NY, USA).

RESULTS
=======

Baseline characteristics
------------------------

A total of 2380 hospitalized patients with all culture-positive ascites were screened from 11 different teaching hospitals between 2012 and 2018. Only 432 SAI episodes were identified in patients with culture-positive acute decompensated cirrhosis and enrolled in this study. The flowchart of patient enrollment is shown in [Fig. 1](#F1){ref-type="fig"}. Based on the infectious sources, cirrhotic patients with SAI were classified as community-acquired (104/432, 24.1%), healthcare-associated (150/432, 34.7%), and nosocomial (178/432, 41.2%). Health care services and previous antibiotics use were more common in patients with healthcare-associated and nosocomial infections than in those with community-acquired infections (*p*\<0.001). Serum white blood cell (WBC) counts, neutrophil counts, international normalized ratios (INR), and Model for End-Stage Liver Disease Sodium (MELD-Na) scores were higher in patients with healthcare-associated and nosocomial infections than in those with community-acquired infections (*p*\<0.05). In these patients, 28-day mortality rates in patients with community-acquired, healthcare-associated, and nosocomial infections were 13.5, 27.3, and 19.1%, respectively (*p*=0.022) ([Table 1](#T1){ref-type="table"}).

Microorganism characteristics
-----------------------------

A total of 455 strains were isolated from the 432 ascitic fluid specimens: 52.3% were GNB, 45.5% gram-positive bacteria (GPB), and 2.2% fungi. The prevalence of GPB infections was significantly higher than GNB infections in patients with HBV-related cirrhosis (*p*=0.019). A tendency toward a higher mortality was observed in patients with GNB infections than in those with GPB infections during hospitalization; however, no difference was observed in 28-day mortality between the two groups (*p*=0.406) ([Supplementary Table 1](#S1){ref-type="supplementary-material"}, only online). GPB infections increased from 37.2% to 54.3%, whereas GNB infections decreased from 60.7% to 43.4% between 2012--2015 and 2016--2018. Fungi were isolated almost equally in the two intervals. We also assessed the trends of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*, fluoroquinolone-resistant (FQR) *E. coli* and *K. pneumoniae*, methicillin-resistant *Staphylococcus aureus* (MRSA), and penicillin-resistant *Streptococcus viridans* (PRSV). Results showed that the percentage of MRSA increased from 0.4% to 0.7%, while ESBL-producing and FQR pathogens (*E. coli* and *K. pneumoniae*) decreased from 10.8% and 11.6% to 5.0% and 5.0%, respectively. The prevalence of PRSV in the two intervals was almost the same ([Fig. 2](#F2){ref-type="fig"}).

GNB infections were classified as MDR and XDR in 16.7% (76/455) and 1.3% (6/455), respectively, and MDR GPB infections comprised 4.4% (20/455). No pan-drug resistant GNB and XDR GPB were identified during the study. XDR GNB infections were significantly and positively correlated with non-survivors (*p*=0.007). Similarly, MDR organisms were isolated more frequently from non-survivor groups with GNB (*p*=0.267) and GPB (*p*=0.455) infections ([Table 2](#T2){ref-type="table"}).

We further investigated the distributions of GNB and GPB between SBP and bacterascites groups. The results showed that GNB were the major pathogens in the SBP group (71.6%), whereas GPB were predominant in the bacterascites group (57.3%), and the differences in GNB or GPB distributions between them were statistically significant (*p*\<0.001). The prevalence of MDR/XDR strains in GNB infections was much higher in the SBP group than in the bacterascites group (*p*=0.002). Interestingly, in patients with bacterascites, the percentage of *Enterococcus spp*. isolates were higher in nosocomial infections than in healthcare-associated and in community-acquired infections. However, *Streptococcus spp*. were detected more common in the community-acquired subgroup than in the healthcare-associated and nosocomial subgroups (*p*\<0.05). Other bacteria distributions among the three subgroups were not statistical significance ([Supplementary Table 2](#S2){ref-type="supplementary-material"}, only online).

The majority of GNB infections were caused by *E. coli* (26.2%) and by *K. pneumoniae* (7.5%). GPB included *Staphylococcus spp*. (17.1%), *Enterococcus spp*. (12.7%), *Streptococcus spp*. (10.1%), and others. *Candida species* accounted for 2.0% (9/455) of all strains ([Supplementary Table 3](#S3){ref-type="supplementary-material"}, only online). ESBL-producing *E. coli* and *K. pneumoniae* were isolated in 72 (15.8%) out of 455 strains and presented less frequently in patients with community-acquired infections (12.1%) than in those with healthcare-associated (17.2%) and nosocomial infections (16.8%). Carbapenem-resistant GNB infections were more frequent in the healthcare-associated and nosocomial groups than in the community-acquired group (*p*=0.005) ([Supplementary Table 4](#S4){ref-type="supplementary-material"}, only online).

Antibiotic susceptibility analysis
----------------------------------

Antibiotic susceptibility of GNB, including *E. coli* and *K. pneumoniae*, was investigated with respect to susceptibility to 18 different antibiotics covering seven main groups. The *E. coli* and *K. pneumoniae* isolates were highly sensitive to meropenem, imipenem, piperacillin/tazobactam, and amikacin, regardless of their ESBL status. Similar results were observed among community-acquired, healthcare-associated, and nosocomial infections; however, non-ESBL-producing agents also showed high sensitivity to third-generation cephalosporins and aztreonam ([Table 3](#T3){ref-type="table"}).

Antibiotic susceptibility of GPB, including *Staphylococcus*, *Streptococcus viridans*, and *Enterococcus*, was determined. The susceptibility of MRSA to fluoroquinolone antibiotics, erythromycin, clindamycin, sulfamethoxazole, and trimethoprim was weaker than that in methicillin-sensitive isolates. However, methicillin-resistant isolates showed good sensitivity to vancomycin and linezolid among community-acquired, healthcare-associated, and nosocomial infections. PRSV were highly susceptible to other antimicrobials, except for erythromycin, clindamycin, tetracycline, and levofloxacin. In addition, similar to other GPB, both *Enterococcus faecium* and *Enterococcus faecalis* were also sensitive to vancomycin and linezolid ([Table 4](#T4){ref-type="table"}).

Predictors of 28-day mortality in patients with acute decompensated cirrhosis with culture-positive SAI
-------------------------------------------------------------------------------------------------------

decompensated cirrhosis with culture-positive SAI In univariate analysis, days of hospital stay before culture-positive SAI, prevalence of XDR isolates, severe hepatic encephalopathy (HE) (grade 2--4), upper gastrointestinal bleeding (UGB), WBC count, neutrophil count, aspartate transaminase (AST), alanine aminotransferase (ALT), serum creatinine, total bilirubin, INR, and Model for End-Stage Liver Disease score (MELD) and MELD-Na scores were significantly correlated with outcomes of patients with acute decompensated cirrhosis who developed culture-positive SAI. Multivariate analysis demonstrated that mortality variables were independently associated with days of hospital stay before culture-positive SAI, UGB, WBC count, INR, ALT, serum creatinine, and total bilirubin ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

The prevalence of MDR pathogens and antibiotic strategies were identified in patients with acute decompensated cirrhosis with culture-positive SAI in our multicenter retrospective study. To the best of our knowledge, this is the most comprehensive and largest contemporary epidemiological survey for this group of patients in China.

Our study indicated that GNB remain the primary pathogens; meanwhile, an increasing prevalence of GPB in SAI was observed. *E. coli* and *K. pneumoniae* represented the highest GNB infections, and *Staphylococcus* was the dominant GPB. These results were different from several single-center studies, which demonstrated *Streptococcus spp*. and *Enterococcus spp*. as the most frequently isolated GPB.[@B22][@B23] Historically, GNB have been isolated in the majority of patients with HBV-related acute decompensated cirrhosis complicated with SAI.[@B22][@B24] However, in this study, GPB were found to be the predominant pathogens. Particularly, an increasing rate of infections caused by GPB and resistant microorganisms had been demonstrated in culture-positive cases of SAI.[@B8][@B12] The prevalence of GPB in our study was lower than that reported (55%) in a recent study;[@B12] however, the increasing trend of GPB infections in culture-positive SAI patients with acute decompensated cirrhosis remains obvious and may be attributed to an exposure to healthcare services and previous antibiotics uses before admission, especially a widespread use of prophylactic antibiotics against GNB in patients with culture-positive SAI. Thus, antibiotics used to manage GPB infections should also be considered in future empirical therapies.

An increase in MDR and XDR bacteria in patients with SBP has been reported.[@B25] As shown in our study, the prevalence of MDR and/or XDR pathogens in patients with culture-positive SBP or bacterascites were 29.6% and 18.2%, respectively. These percentages were higher than those reported among patients with SBP,[@B19][@B26][@B27] but lower than that reported (25%) among patients with bacterascites by Oey, et al.[@B8] These results emphasized an urgent need to control the increase of drug resistant bacteria in patients with SAI. Additionally, our results indicated that MDR organisms are more prevalent in nosocomial and healthcare-associated patients with SAI than in community-acquired patients. The prevalence of ESBL-producing organisms in community-acquired infections was much higher than that reported,[@B28] which may be attributed to the extensive use of third-generation cephalosporins in China. Furthermore, patients with healthcare-associated infections had a higher 28-day mortality than patients with community-acquired SAI. Thus, attention should be paid to patients with healthcare-associated and nosocomial SAI.

Third-generation cephalosporins, piperacillin-tazobactam, and carbapenems are recommended in the recent EASL guidelines for the treatment of patients with decompensated cirrhosis with SBP.[@B13] However, the increase in XDR and MDR strains challenge the recommended antibiotics from the guidelines. Our findings showed that ESBL-producing *E. coli* and *K. pneumoniae* accounted for 15.8%. A significant number of ESBL-producing strains exhibited low sensitivity to third-generation cephalosporins and/or quinolones, especially pathogens in community-acquired infections. In the present study, ceftazidime, cefepime, aztreonam, and amikacin were recommended for first-line antibiotic treatment for non-MDR GNB infections. Considering the high mortality, piperacillin/tazobactam and carbapenems should be considered for MDR GNB infections in community-acquired SAI and healthcare-associated or nosocomial SAI, respectively, which is in accordance with EASL guidelines. However, unlike the ESAL guidelines that recommend carbapenems combined with glycopeptides or daptomycin or linezolid, vancomycin or linezolid should be considered for GPB infections, regardless of drug-resistance status and type of infections.

Previous studies have reported on independent risk factors in patients with SBP;[@B1][@B29] however, no study has evaluated the specific risk factors for culture-positive SAI in patients with acute decompensated cirrhosis. In our series, severe HE, UGB, WBC count, serum creatinine, and INR were independently associated with 28-day all-cause mortality, and these results emphasized the importance of the timely treatment in complications. More importantly, reducing days of hospital stay before SAI, which meant early diagnosis and treatment, was also closely related to 28-day mortality.

Our study had several limitations. First, our study aimed to analyze the microbiological characteristics of patients with culture-positive SAI, thus culture-negative patients with SAI were excluded from our study. Second, we included *Staphylococcus* because this strain could be isolated from both the blood and ascitic fluid samples obtained from one patient. Furthermore, exogenous contamination related to invasive procedures, such as traumatic paracentesis, was unlikely to account for any of the culture-positive SAI cases, and no effective methods to distinguish contaminants from pathogens because SAI may be caused by *Staphylococcus* with low virulence in susceptible patients. Finally, a few clinical results, such as AST and ALT, were missing in patient records, but did not significantly impact the results.

In conclusion, GNB were the most common pathogens, with a growing proportion of SAIs caused by GPB and MDR/XDR GNB. Healthcare-associated and nosocomial infections showed a high prevalence of MDR organisms and exhibited differences in 28-day mortality, compared to community-acquired infections. Carbapenems, piperacillin/tazobactam, and amikacin were more suitable for the treatment of culture-positive SAI with GNB infections, whereas vancomycin and linezolid were the best choices for GPB infections. All identified independent risk factors could be utilized to develop a multiple clinical risk evaluation system to help clinicians identify the highest-risk subsets of patients.
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###### Clinical Characteristics of Patients with Community-Acquired, Healthcare-Associated, and Nosocomial Culture-Positive Spontaneous Ascitic Infections

![](ymj-61-145-i001)

                                         Community-acquired (n=104)   Healthcare-associated (n=150)   Nosocomial (n=178)   *p* value
  -------------------------------------- ---------------------------- ------------------------------- -------------------- -----------
  Age (yr)                               55±11.5                      56±12.6                         56±11.6              0.419
  Male/female                            80/24                        107/43                          125/53               0.460
  Exposure to health care services^\*^   22 (21.2)                    89 (59.3)                       93 (52.2)            \<0.001
  Previous antibiotics uses^†^           2 (1.9)                      33 (22.0)                       30 (16.9)            \<0.001
  Serum WBC (×10^9^/L)                   5.2 (3.2--8.5)               6.8 (4.3--10.7)                 6.8 (4.1--10.0)      0.011
  Neutrophil (×10^9^/L)                  3.7 (1.9--6.6)               5.2 (2.6--8.9)                  4.7 (2.8--8.0)       0.014
  PLT (×10^9^/L)                         88 (56.3--114.7)             76 (49.9--113.8)                73 (48.8--102.0)     0.233
  AST (U/L)                              53.3 (32.6--87.4)            54.2 (35.3--98.4)               44.0 (29.5--83.9)    0.155
  ALT ( U/L)                             29.4 (19.0--65.6)            35.5 (22.0--66.2)               27.0 (17.0--54.4)    0.109
  Total bilirubin (mg/dL)                3.0 (1.5--7.1)               4.1 (2.1--9.1)                  3.8 (1.8--9.1)       0.077
  Serum creatinine (mg/dL)               0.9 (0.7--1.3)               1.0 (0.7--1.6)                  1.0 (0.7--1.4)       0.535
  Albumin (g/L)                          26.5±8.0                     28.0±10.5                       28.8±5.4             0.071
  INR                                    1.6±0.5                      1.9±0.8                         1.8±0.8              0.016
  MELD                                   15±8.6                       18±9.8                          17±9.4               0.061
  MELD-Na                                21±7.1                       24±7.9                          23±7.7               0.001
  Child-Pugh score                       10±2.0                       11±2.0                          10±1.9               0.175
  28-day mortality                       14 (13.5)                    41 (27.3)                       34 (19.1)            0.022

WBC, white blood cell; PLT, platelet; AST, aspartate transaminase; ALT, alanine aminotransferase; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; MELD-Na, Model for End-Stage Liver Disease Sodium.

Categorical variables: number (percentage). Continuous variables: means±SD, median and interquartile ranges.

^\*^Health care services are defined as hospitalization or contact with the health care system (emergency department, nursing home, and clinic) within 2 weeks prior to admission. ^†^Previous antibiotics are defined as any antibiotics used for more than 2 days during the 14 days before admission.

###### Distributions of Resistance Microorganisms between Survivors and Non-Survivors
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  Microorganism distribution         All (n=455)   Survivors (n=329)   Non-survivors (n=126)   *p* value
  ---------------------------------- ------------- ------------------- ----------------------- -----------
  GNB                                238 (52.3)    168 (51.1)          70 (55.6)               0.391
   *Escherichia coli* (FQR)          68 (14.9)     43 (13.1)           25 (19.8)               0.070
   *Escherichia coli* (ESBL)         61 (13.4)     39 (11.9)           22 (17.5)               0.116
   *Klebsiella pneumoniae* (FQR)     8 (1.8)       5 (1.5)             3 (2.4)                 0.691
   *Klebsiella pneumoniae* (ESBL)    11 (2.4)      7 (2.1)             4 (3.2)                 0.506
   *Acinetobacter baumannii* (XDR)   3 (0.7)       0                   3 (2.4)                 0.021
   *Enterobacteriaceae* (CRE)        2 (0.4)       0                   2 (1.6)                 0.076
   MDR GNB^\*^                       76 (16.7)     51 (15.5)           25 (19.8)               0.267
   XDR GNB^\*^                       6 (1.3)       1 (0.3)             5 (4.0)                 0.007
  GPB                                207 (45.5)    156 (47.4)          51 (40.5)               0.183
   *Staphylococci* (MRSCoN)          37 (8.1)      30 (9.1)            7 (5.6)                 0.213
   *Staphylococcus aureus* (MRSA)    5 (1.1)       3 (0.9)             2 (1.6)                 0.620
   *Streptococcus viridans* (PRSV)   11 (2.4)      8 (2.4)             3 (2.4)                 \>0.999
   MDR GPB^†^                        20 (4.4)      13 (4.0)            7 (5.6)                 0.455
  Fungi                              10 (2.2)      5 (1.5)             5 (4.0)                 0.149

FQR, fluoroquinolone-resistant; ESBL, extended-spectrum β-lactamase; XDR, extensively drug resistant; CRE, carbapenemase resistant *Enterobacteriaceae*; MRSCoN, methicillin resistant coagulase-negative *Staphylococcus*; MRSA, methicillin-resistant *Staphylococcus aureus*; PRSV, penicillin-resistant *Streptococcus viridans*; GNB, gram-negative bacteria; GPB, gram-positive bacteria; MDR GNB, multidrug resistant GNB; XDR GNB, extensively drug resistant GNB.

Categorical variables: number (percentage).

^\*^MDR and XDR GNB including *Enterobacteriaceae*, *Pseudomonas aeruginosa*; *Acinetobacter spp*. ^†^MDR GPB including *Enterococcus spp*. and *Staphylococcus aureus*.

###### In Vitro Susceptibility Rates (%) of Gram-Negative Isolates
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  Antibiotics   *Escherichia coli* and *Klebsiella pneumoniae*                               
  ------------- ------------------------------------------------ ------ ------ ------ ------ ------
  AMP           0.0                                              35.0   0.0    15.2   0.0    37.0
  PIP           0.0                                              62.5   0.0    60.0   0.0    46.2
  SAM           27.3                                             66.7   12.5   63.3   8.3    65.4
  TZP           92.3                                             95.0   84.0   97.0   83.3   92.3
  CZO           0.0                                              50.0   0.0    69.2   0.0    66.7
  CAZ           46.2                                             100    29.6   100    41.9   100
  FEP           38.5                                             100    36.0   100    29.0   100
  ATM           18.2                                             95.0   20.0   100    33.3   96.2
  AMK           81.8                                             100    84.0   94.1   87.1   100
  GEN           61.5                                             80.0   36.0   74.2   43.3   65.4
  IPM           100                                              100    96.3   100    93.5   100
  MEM           100                                              100    100    100    92.9   100
  CIP           23.1                                             75.0   29.6   70.6   31.3   55.6
  LVX           23.1                                             75.0   29.6   75.8   31.3   55.6
  SXT           23.1                                             57.9   24.0   51.6   25.0   50.0

AMP, ampicillin; PIP, piperacillin; SAM, ampicillin/sulbactam; TZP, piperacillin/tazobactam; CZO, cefazolin; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; AMK, amikacin; GEN, gentamicin; IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; LVX, levofloxacin; SXT, sulfamethoxazole and trimethoprim; ESBL, extended-spectrum β-lactamase.

###### In Vitro Susceptibility Rates (%) of Gram-Positive Isolates
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  Gram-positive isolates   Type   PEN    CIP    LVX    MFX    TET    ERY    CLI    LNZ   VAN    GEN    RIF    SXT
  ------------------------ ------ ------ ------ ------ ------ ------ ------ ------ ----- ------ ------ ------ ------
  *Staphylococcus*                                                                                            
   Community-acquired      MRS    0.0    70.0   60.0   60.0   76.9   23.1   38.5   100   100    84.6   92.3   45.5
  MSS                      33.3   88.9   87.5   100    66.7   45.5   70.0   100    100   100    100    81.8   
   Healthcare-associated   MRS    0.0    62.5   62.5   57.1   77.8   10.0   40.0   100   100    70.0   77.8   70.0
  MSS                      20.0   92.9   100    100    83.3   21.4   80.0   100    100   100    100    92.3   
   Nosocomial              MRS    10.5   41.2   44.4   47.1   88.2   10.5   47.4   100   94.4   77.8   100    70.6
  MSS                      0.0    66.7   71.4   83.3   87.5   25.0   62.5   100    100   71.4   87.5   62.5   

                            Type   PEN   CIP    LVX    MFX   TET    ERY    CLI   LNZ    VAN   GEN    RIF   SXT
  ------------------------- ------ ----- ------ ------ ----- ------ ------ ----- ------ ----- ------ ----- -----
  *Enterococcus faecium*    \-     5.3   7.4    0.0    \-    50.0   3.6    \-    93.3   100   40.7   \-    \-
  *Enterococcus faecalis*   \-     100   66.7   87.5   \-    25.0   20.0   \-    100    100   42.9   \-    \-

                             Type   CAZ    CRO    FEP    LVX    TET    ERY    CLI    LNZ    VAN    CHL
  -------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ -----
  *Streptococcus viridans*   PRSV   90.9   87.5   100    63.6   45.5   9.1    9.1    90.9   90.9   100
  PSSV                       88.9   87.5   88.9   70.0   50.0   20.0   30.0   90.0   90.0   87.5   

PEN, penicillin; CIP, ciprofloxacin; LVX, levofloxacin; MFX, moxifloxacin; TET, tetracycline; ERY, erythromycin; CLI, clindamycin; LNZ, linezolid; VAN, vancomycin; GEN, gentamicin; RIF, rifampin; SXT, sulfamethoxazole and trimethoprim; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; CHL, chloramphenicol; MRS, methicillin-resistant *Staphylococcus*; MSS, methicillin-sensitive *Staphylococcus*; PRSV, penicillin-resistant *Streptococcus viridans*; PSSV, penicillin-sensitive *Streptococcus viridans*.

###### Predictors of 28-Day Mortality in Univariate and Multivariate Analysis of Cirrhotic Patients with Culture-Positive SAI
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  Predictors                         Univariate analysis         Multivariate analysis                              
  ---------------------------------- --------------------------- ----------------------- -------------------------- -------------
  Age                                0.998 (0.981--1.015)        0.792                                              
  Sex                                0.975 (0.620--1.535)        0.914                                              
  Exposure to health care services   1.294 (0.851--1.966)        0.228                                              
  Previous antibiotics use           1.248 (0.704--2.212)        0.447                                              
  Days of hospital stay before SAI   0.956 (0.916--0.998)^\*^    0.039^\*^               0.925 (0.881--0.972)^\*^   0.002^\*^
  Prevalence of XDR isolates         3.441 (1.082--10.946)^\*^   0.036^\*^               2.410 (0.702--8.273)       0.162
  Prevalence of MDR isolates         1.369 (0.857--2.187)        0.189                                              
  BSIs                               0.722 (0.292--1.782)        0.479                                              
  Pneumonia                          1.295 (0.809--2.073)        0.282                                              
  UTIs                               1.583 (0.499--5.030)        0.436                                              
  HE (Grade 2--4)                    2.372 (1.359--4.139)^\*^    0.002^\*^               1.568 (0.839--2.930)       0.158
  UGB                                2.072 (1.125--3.819)^\*^    0.019^\*^               2.676 (1.382--5.180)^\*^   0.003^\*^
  Serum WBC                          1.065 (1.036--1.094)^\*^    \<0.001^\*^             1.053 (1.020--1.086)^\*^   0.001^\*^
  Neutrophil                         1.046 (1.031--1.062)^\*^    \<0.001^\*^                                        
  PLT                                0.999 (0.996--1.002)        0.412                                              
  AST                                1.001 (1.001--1.002)^\*^    \<0.001^\*^             0.999 (0.997--1.000)       0.081
  ALT                                1.002 (1.001--1.003)^\*^    \<0.001^\*^             1.002 (1.000--1.003)^\*^   0.025^\*^
  Albumin                            0.965 (0.930--1.001)        0.059                   0.965 (0.927--1.006)       0.091
  Serum creatinine                   1.680 (1.457--1.938)^\*^    \<0.001^\*^             1.508 (1.292--1.761)^\*^   \<0.001^\*^
  Total bilirubin                    1.073 (1.055--1.091)^\*^    \<0.001^\*^             1.059 (1.039--1.079)^\*^   \<0.001^\*^
  INR                                1.284 (1.202--1.372)^\*^    \<0.001^\*^             1.295 (1.141--1.470)^\*^   \<0.001^\*^
  MELD score                         1.124 (1.101--1.147)^\*^    \<0.001^\*^                                        
  MELD-Na score                      1.170 (1.136--1.206)^\*^    \<0.001^\*^                                        

SAI, spontaneous ascitic infection; BSIs, blood stream infections; UTIs, urinary tract infections; HE (Grade 2--4), hepatic encephalopathy (Grade 2--4); UGB, upper gastrointestinal bleeding; HR, hazard ratio; CI, confidence interval.

MELD scores, MELD-Na scores and neutrophil were not included in the multivariate model to avoid potential collinearities.

^\*^*p*-values \<0.05 and corresponding HR are indicated.
